Janus Kinase Inhibitor-Induced Acne in Inflammatory Bowel Disease: An International, Multicenter, Retrospective Cohort Study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Honap Sailish, Temido Maria José, Shakweh Eathar, Badrulhisham Fakhirah, Shields Natalie, Mehta Sonia, McBride Jodie, Uzzan Mathieu, Lukáš Milan, Fumery Mathurin, Nogami Akira, Kobayashi Taku, Nancey Stephane, Neves Joana Camões, Mendes João Martins, Wegener Birte-Antina, Bergereau Emilie, Fernandes Rita, Kuzhiyanjal Anish John Kuriakose, Vieujean Sophie, Spencer Ashley, Baillie Samantha, Estevinho Maria Manuela, Simão Inês, O'Neill Catarina, Gututui Madalina, Thompson Ellen, Jama Amina, Chai Ningyu, Pavlidis Polychronis, D'Amico Ferdinando, Limdi Jimmy, Magro Fernando, Sebastian Shaji, Digby-Bell Jonathan, Parkes Gareth C, Din Shahida, Hart Ailsa, Peyrin-Biroulet Laurent, JAKne International Study Group
Аннотация
METHODS: This international, multicenter, retrospective cohort study consecutively enrolled JAK-inhibitor-treated patients with IBD who subsequently developed acne. The primary objective was to evaluate the clinical characteristics of acne. Secondary objectives included determining acne prevalence, impact on quality of life, and antiacne treatment effectiveness.
RESULTS: Among 2183 JAK inhibitor-treated patients with IBD, 272 developed acne. The crude prevalence rates of acne were 15.9% for upadacitinib, 4.3% for tofacitinib, and 1.9% for filgotinib, with dose-dependent relationships observed for upadacitinib and tofacitinib. Acne predominantly affected patients aged 30-50 years; most cases were mild-moderate in severity. A prior history of acne vulgaris was associated with significantly increased odds of developing severe JAK inhibitor-associated acne (odds ratio, 4.88; 95% confidence interval, 2.88-31.7; P = .0003) and acne-related skin complications (odds ratio, 3.92; 95% confidence interval, 1.56-10.11; P = .004). One-third of patients reported a negative psychosocial impact, and 40% received pharmacologic intervention. Eighteen percent of patients who developed acne required JAK inhibitor dose reduction or discontinuation, although most did not have severe disease.
CONCLUSIONS: This is the first study characterizing this adverse event in JAK inhibitor-treated patients with IBD and presents the largest cohort of JAK inhibitor-induced acne cases across all immune-mediated diseases. Acne is a common adverse effect resulting in significant psychological burden. Early identification, proactive counseling, and timely interventions, such as dose reduction or referral to dermatology, are crucial in managing this side effect.